arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Vericel Corp

VCEL
$45.06 ▲ +0.34 (+0.77%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
69 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
65
Health
Fair
Neutral
auto_awesome

Analytical Summary

Vericel Corp shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $2.3B
Dividend Yield
Revenue Growth 22.5%
Op. Margin 0.6%
ROIC 0.1%
FCF / Share $0.28
Trailing P/E 1126.5x
Price / Book 6.2x
FCF Yield 0.6%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

69-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$77.46M
↑ +22.5%
Net Income Profit after all expenses
$-6.30M
↑ +44.0%
Operating Margin Operating profit as % of sales
0.6%
↑ +104.8% 39th
FCF / Share Free cash flow per share
$0.28
↓ -6.3%
Long-Term Debt Long-term obligations
$14.42M
↓ -7.9%

Health Breakdown

Profitability
50
Returns
53
Financial Health
90
Cash Quality
80

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 19 years · 69 quarters